---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-24-000015"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2024-05-20T23:59:59+00:00"
generated_at: "2026-06-01T12:53:13.850147+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NovoCure's METIS phase 3 trial data in brain metastases to be presented at ASCO 2024

## Summary
- Abstract for METIS phase 3 trial in brain metastases from NSCLC available May 23 on ASCO website.
- Oral presentation scheduled for June 3 at 10:24 AM CDT during CNS Tumors session.
- No data disclosed yet; trial results are pending presentation at ASCO.

## SEC filing metadata
- accession: 0001645113-24-000015
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2024-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000015/0001645113-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000015/nvcr-20240520.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-24-000015
- JSON: https://secwatch.observer/filing/0001645113-24-000015.json
- Plain text: https://secwatch.observer/filing/0001645113-24-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.